CJC-1295 (no DAC) / Mod GRF(1-29)
Fat LossShort-acting GHRH analogExperimental
Modified GRF(1–29) without the DAC albumin-binding moiety. Shorter GH pulses than DAC-CJC. Not FDA-approved. WADA S2.
For research use only.
Key Facts
- CAS
- 863288-34-0
- Molecular Weight (MW)
- ≈3368 g/mol
- Half-life
- Short (hours) vs DAC variant
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- GHRH receptor
Overview
Modified GRF(1–29) without the DAC albumin-binding moiety. Shorter GH pulses than DAC-CJC. Not FDA-approved. WADA S2.
Protocol
- Dosage Range
- Not established for approved medical use
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Four amino-acid substitutions stabilize GRF(1–29) against DPP-IV, producing brief GHRH-receptor activation and physiologic-like GH pulses when dosed frequently.
Targets
GHRH receptor
Studies
- CJC-1295 / modified GRF GH secretagogue literature— Journal/year not available
Benefits
Pulsatile GH-axis research
Potential Side Effects
- Flushing
- Transient GH-related edema
References
- PMID 16352683External link · Year —
- WADA Prohibited List 2026External link · Year —